Clinical Trials for PharmaEssentia

Explore 10 clinical trials worldwide

Showing 1-10 of 10 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: PharmaEssentia

Clinical Trials (10)

NCT06290765
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
PHASE4Not yet recruiting
70 participants
Started: Feb 1, 2026 · Completed: Jun 30, 2027
2 conditions1 sponsor0 locations
NCT07047885
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
PHASE1Recruiting
38 participants
Started: Aug 27, 2025 · Completed: Jun 30, 2028
1 condition2 sponsors1 location
NCT06468033
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
PHASE3Recruiting
150 participants
Started: Jul 18, 2025 · Completed: Sep 30, 2028
2 conditions1 sponsor1 location
NCT07053904
Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors
PHASE1Enrolling by invitation
54 participants
Started: Apr 21, 2025 · Completed: Dec 31, 2029
1 condition2 sponsors2 locations
NCT06665776
HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan
N/ARecruiting
1,200 participants
Started: Mar 14, 2023 · Completed: Dec 31, 2025
1 condition1 sponsor6 locations
NCT05481151
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
PHASE3Active, not recruiting
111 participants
Started: Oct 26, 2022 · Completed: Jul 31, 2027
1 condition1 sponsor23 locations
NCT05482971
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
PHASE2Active, not recruiting
91 participants
Started: Sep 29, 2022 · Completed: Mar 31, 2027
1 condition1 sponsor34 locations
NCT05485948
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
PHASE2Active, not recruiting
49 participants
Started: Oct 8, 2021 · Completed: Jul 31, 2027
1 condition1 sponsor14 locations
NCT04655092
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
PHASE3Recruiting
67 participants
Started: Jan 19, 2021 · Completed: Jun 30, 2026
1 condition1 sponsor6 locations
NCT04285086
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
PHASE3Active, not recruiting
174 participants
Started: Aug 25, 2020 · Completed: Aug 31, 2029
1 condition1 sponsor65 locations